IDEAYA Biosciences Inc (IDYA) FinancialsIDYAIDEAYA Biosciences Inc

IDEAYA Biosciences, Inc. (IDYA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is WRN, accounting for 56.0% of total sales, equivalent to $2.20M. Other significant revenue streams include MAT2A and Pol Theta. Understanding this composition is critical for investors evaluating how IDYA navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, IDEAYA Biosciences, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1497.28%, while the net margin is -1368.56%. These profitability ratios, combined with a Return on Equity (ROE) of -16.22%, provide a clear picture of how effectively IDYA converts its operational activities into shareholder value.

In the context of the broader market, IDYA competes directly with industry leaders such as VKTX and XENE. With a market capitalization of $3.27B, it holds a significant position in the sector. When comparing efficiency, IDYA's gross margin of 100.00% stands against VKTX's N/A and XENE's N/A. Such benchmarking helps identify whether IDEAYA Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown volatility in revenue, with a significant drop to $0 in Q1 and Q2 of 2025, followed by a recovery to $207.83 million in Q3 2025. However, net income remains negative, with a recent loss of $112.45 million in Q2 2026, highlighting ongoing financial challenges.